New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 7, 2014
13:18 EDTSNY, REGN, AEGRRegeneron disclosed FDA contact about PCSK9 adverse events previously
Regeneron (REGN) stated in its 10-K filing on February 13 after the market close that the company its partner Sanofi (SNY) have been advised by the FDA that it has become aware of neurocognitive adverse events in the PCSK9 inhibitor class. Similar wording was included in a regulatory filing made today by Sanofi and may be a factor in the volatility seen in shares of Regeneron this afternoon. Shares of Regeneron are off their earlier lows but remain down about 7.8% near $312 per share. Shares of Aegerion (AEGR) spiked as Regeneron shares sold off, but are off their earlier highs. Aegerion remains up about 4.5% near $52.50 in afternoon trading.
News For SNY;REGN;AEGR From The Last 14 Days
Check below for free stories on SNY;REGN;AEGR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 21, 2014
10:02 EDTREGNOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Adeptus Health (ADPT) initiated with a Buy at Dougherty... Amphastar (AMPH) initiated with a Buy at Jefferies... Eclipse Resources (ECR) initiated with a Neutral at SunTrust... Fidelity National (FNF) initiated with a Buy at SunTrust... First American (FAF) initiated with a Buy at SunTrust... GoPro (GPRO) initiated with a Hold at Stifel... Imprivata (IMPR) initiated with an Outperform at Wells Fargo... Lifetime Brands (LCUT) initiated with a Buy at Sidoti... Materialise (MTLS) initiated with a Buy at BB&T... Regeneron (REGN) initiated with a Buy at Argus... STAG Industrial (STAG) initiated with a Buy at Sandler O'Neill... Signature Group (SGGH) initiated with a Buy at B. Riley... TCP International (TCPI) initiated with a Buy at Canaccord... Tessera (TSRA) initiated with a Buy at Craig-Hallum... Xunlei (XNET) initiated with a Perform at Oppenheimer.
07:42 EDTREGNRegeneron initiated with a Buy at Argus
Target $375.
07:11 EDTSNYInternational Society of DNA Vaccines to hold a conference
Subscribe for More Information
July 18, 2014
06:10 EDTREGNRegeneron announces results from Phase 3 VIVID-DME trial of EYLEA
Subscribe for More Information
July 16, 2014
09:03 EDTSNYSanofi held talks on mature drugs with Abbott, Mylan, PE firms, Reuters says
Sanofi (SNY) has shopped an $8.5B portfolio of mature drugs to Abbott (ABT), Mylan (MYL) and private equity firms, according to Reuters, citing an internal company document circulated by the CGT union. Sanofi is considering whether to sell, carve out or create a joint venture for the portfolio of about 200 drugs, but a Sanofi spokesman said no decision has yet been made, the report noted. Reference Link
July 15, 2014
10:56 EDTAEGRFed calls small cap social media, biotech valuations 'stretched'
The Board of Governors of the Federal Reserve in its Monetary Policy Report dated today said valuation metrics in "some sectors" appear substantially stretched, "particularly those for smaller firms in the social media and biotechnology industries, despite a notable downturn in equity prices for such firms early in the year." A later part in the document reads, "Equity valuations of smaller firms as well as social media and biotechnology firms appear to be stretched, with ratios of prices to forward earnings remaining high relative to historical norms." The specific targeting of sectors by the Fed seems to be having an impact on stocks in the social media and biotech spaces. Shares of Yelp (YELP) are down over 5% to $67.51, while Twitter (TWTR) and Facebook (FB) are each down 2%. Celgene (CELG) and Amgen (AMGN) are leading the biotech space lower with pullbacks of greater than 1%.
July 11, 2014
11:31 EDTAEGROptions with increasing implied volatility
Options with increasing implied volatility: INO AEGR UBNT INVN WTW OREX GNC CREE SD SAN
July 10, 2014
06:06 EDTAEGRWestfield Capital Management reports 10.88% passive stake in Aegerion
Subscribe for More Information
July 9, 2014
17:02 EDTREGN, SNYRegeneron, Sanofi announce positive results from Phase 2b study of Dupilumab
Subscribe for More Information
July 8, 2014
13:46 EDTSNYSanofi files patent infringement suit against Eli Lilly, Reuters says
Subscribe for More Information
08:05 EDTSNYSanofi announces FDA accepted Toujeo NDA
Sanofi announced that the FDA has accepted for review the company's New Drug Application for Toujeo, an investigational basal insulin. The acceptance of the NDA follows the acceptance of the marketing authorization dossier for Toujeo by the European Medicines Agency for EU countries on May 27. The NDA for Toujeo is based on results from the EDITION clinical trial program, which is a worldwide and extensive series of Phase III studies evaluating the efficacy and safety of Toujeo in over 3,500 people.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use